JPRN-UMIN000003698
Completed
Phase 2
Phase II Study of Bevacizumab in Combination with Carboplatin plus oral S1 in Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung Cancer - Phase II Stydy of Bevacizumab Combination with Carboplatin plus oral S1 in Lung Cancer. (HCC1002)
Hyogo Cancer Center,Depatrment of Thoracic Oncology0 sites45 target enrollmentJune 2, 2010
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Chemo-Naive Patients with Non-Squamous Non-Small-Cell Lung Cancer
- Sponsor
- Hyogo Cancer Center,Depatrment of Thoracic Oncology
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Pulmonary fibrosis detected by chest CT 2\)History of drug induced interstitial pneumonia 3\)History of severe drug allergy 4\)History of active infection or other serious complication 5\)History of poorly controlled pleural effusion, pericardial effusion, and ascites 6\)Treated by flucytosine(5\-FC) 7\)History of continuous (watery) diarrhea 8\)History of ileus 9\)History of severe heart disease(uncontrollable arrhythmia, uncontrollable angina pectoris, heart failure, etc) 10\)Uncontrollable hypertension 11\)Uncontrollable diabetes mellitus 12\)Current or previous history of hemoptysis or hemosputum 13\)Current or previous (within the last 1 year) history of symptomatic cerebrovascular disease 14\)Current or previous (within the last 1 year) history of GI perforation 15\)Symptomatic brain metastasis 16\)Traumatic fracture of unrecovery 17\)The operation has been scheduled during the examination period 18\)Tumor invasive to the chest Laege bleed vessel.Cavity inbrain or lung tumor 19\)Evidence of bleeding diathesis or coagulopathy 20\)Thorombosis that need to treat 21\)History of active double cancer with in 5 years 22\)History of active psychological disease 23\)History of pregnancy or lactation 24\)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II Study of Bevacizumab in Combination with First-line Platinum-Doublet Chemotherapy in Non-squamous NSCLC Patients with Asymptomatic Untreated Brain Metastases.non-small cell lung cancerJPRN-UMIN000009828Osaka Prefectural Medical Center for Respiratory and Allergic Diseases25
Completed
Phase 2
A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIson-squamous Non-small-cell Lung CancerJPRN-UMIN000003263Hanshin Cancer Study Group30
Recruiting
Phase 2
A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapyon-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000005486Hiroshima citizens hospital Department of Medical Oncology34
Recruiting
Not Applicable
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
Active, not recruiting
Not Applicable
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA